Fuss Brands Corp. (FBDS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
80 BROAD STREET NEW YORK, NY 10004 |
| State of Incorp. | NV |
| Fiscal Year End | October 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 1/31/2025 MRQ | 10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 1,440 | 9,448 | 35,539 | |||||
| Cash and cash equivalent | 1,440 | 9,448 | 35,539 | |||||
| Prepaid expense | 226,740 | 129,917 | ||||||
| Total current assets: | 228,180 | 139,365 | 35,539 | |||||
| Noncurrent Assets | ||||||||
| Other undisclosed assets | (1) | |||||||
| TOTAL ASSETS: | 228,180 | 139,364 | 35,539 | |||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 175,104 | 262,969 | 1,045 | |||||
| Accounts payable | 13,860 | 105,991 | 1,045 | |||||
| Accrued liabilities | 161,244 | 156,978 | ||||||
| Deferred revenue | 176,658 | 176,658 | ||||||
| Debt | 50,000 | 50,000 | ||||||
| Due to related parties | ✕ | ✕ | ✕ | 98,381 | 31,438 | |||
| Other undisclosed current liabilities | 513,739 | 98,380 | ||||||
| Total current liabilities: | 915,501 | 588,007 | 99,426 | 31,438 | ||||
| Noncurrent Liabilities | ||||||||
| Other undisclosed noncurrent liabilities | 1 | |||||||
| Total noncurrent liabilities: | 1 | |||||||
| Total liabilities: | 915,502 | 588,007 | 99,426 | 31,438 | ||||
| Equity | ||||||||
| Equity, attributable to parent, including: | (687,322) | (448,643) | (63,887) | (31,438) | ||||
| Preferred stock | 824 | 834 | 838 | 1,000 | ||||
| Common stock | 19,090 | 19,090 | 14,884 | 37,240 | 37,240 | |||
| Additional paid in capital | 14,803,903 | 12,287,167 | 11,997,559 | 11,704,909 | ||||
| Accumulated deficit | (15,435,250) | (12,679,846) | (12,174,648) | (12,067,237) | (11,742,149) | |||
| Other additional capital | 12,170,928 | |||||||
| Other undisclosed equity, attributable to parent | (75,889) | (75,888) | (75,889) | |||||
| Total equity: | (687,322) | (448,643) | (63,887) | (31,438) | ||||
| TOTAL LIABILITIES AND EQUITY: | 228,180 | 139,364 | 35,539 | |||||
Income Statement (P&L) (USD)
| 1/31/2025 TTM | 10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | (43,650) | ||||||
| Operating expenses | (2,750,359) | (503,078) | (107,411) | (325,088) | |||
| Other undisclosed operating income | 43,650 | ||||||
| Operating loss: | (2,750,359) | (503,078) | (107,411) | (325,088) | |||
| Interest and debt expense | (2,119) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (2,750,359) | (505,197) | (107,411) | (325,088) | |||
| Other undisclosed loss from continuing operations before income taxes | (5,045) | ||||||
| Loss from continuing operations: | (2,755,404) | (505,197) | (107,411) | (325,088) | |||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (325,088) | ✕ | |
| Net loss attributable to parent: | (2,755,404) | (505,197) | (107,411) | (325,088) | |||
| Other undisclosed net income available to common stockholders, basic | 1,010,394 | 214,822 | 650,176 | ||||
| Net income (loss) available to common stockholders, diluted: | (2,755,404) | 505,197 | 107,411 | 325,088 | |||
Comprehensive Income (USD)
| 1/31/2025 TTM | 10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (2,755,404) | (505,197) | (107,411) | (325,088) | |||
| Comprehensive loss, net of tax, attributable to parent: | (2,755,404) | (505,197) | (107,411) | (325,088) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.